Literature DB >> 26312624

Obtaining Lissamine Green 1% Solution for Clinical Use.

Michael Stock1, David Salvay, Bradley Shoss, Kisha Piggott, Susan M Culican.   

Abstract

PURPOSE: With new compounding pharmacy laws, the only economically feasible approach to using lissamine is through dye-impregnated strips. This research aims to determine the concentration of lissamine that can be obtained using a single commercially available lissamine strip. With the optimal vital staining requiring 1% concentration of lissamine, we sought to obtain this concentration using supplies in an ordinary ophthalmology clinic.
METHODS: A standard curve was generated using compounded lissamine green 1% solution. Serial dilutions were made with 3 different diluents and measured using a spectrophotometer at a wavelength of 633 μm. Combinations of the number of strips, amount of solvent, and absorption time were performed to obtain a 1% solution. Cost analyses were performed to select the most economical method.
RESULTS: Single lissamine strips wetted with any of the diluents produced 0.17% ± 0.05% (95% confidence interval) lissamine solution, a 5-fold weaker concentration than the optimal for vital staining. Combinations of 4 strips in 200 μL (4 drops) for 1 minute and 2 strips in 200 μL for 5 minutes were found to reach concentrations of 1%. Cost analysis showed that the 2 strip/4 drops/5 minutes method costs $0.67 and the 4 strips/4 drops/1 minute method $1.27.
CONCLUSIONS: Use of a single lissamine strip leads to suboptimal concentrations for vital staining. With only the addition of disposable microcentrifuge tubes to the clinical setting, ophthalmologists can make 1% solutions of lissamine. This solution is both more economical and in compliance with both state and national compounding laws.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26312624     DOI: 10.1097/ICO.0000000000000588

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Predictors for Dry Eye Diseases in Patients with Systemic Sclerosis.

Authors:  Wipada Laovirojjanakul; Yosanan Yospaiboon; Orapin Anutarapongpan; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara; Chingching Foocharoen
Journal:  Clin Ophthalmol       Date:  2022-10-17

2.  Ocular Clinical Signs and Diagnostic Tests Most Compatible With Keratoconjunctivitis Sicca: A Latent Class Approach.

Authors:  John A Gonzales; Stephen C Shiboski; Vatinee Y Bunya; Esen K Akpek; Jennifer Rose-Nussbaumer; Gerami D Seitzman; Lindsey A Criswell; Caroline H Shiboski; Thomas M Lietman
Journal:  Cornea       Date:  2020-08       Impact factor: 3.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.